Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

4
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018

2018-07-17 globenewswire
LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018.
EYRYY ERYP

0
Erytech Pharma (ERYP) Confirms Strategic Focus Of Eryaspase On Solid Tumors And Ceases Development In Acute Lymphoblastic Leukemia - Slideshow

2018-06-26 seekingalpha
The following slide deck was published by Erytech Pharma S.A. ADS in conjunction with this event.
EYRYY ERYP

0
ERYTECH confirme l’orientation stratégique d’eryaspase dans les tumeurs solides et interrompt ses développements dans la Leucémie Aiguë Lymphoblastique (LAL)

2018-06-24 globenewswire
LYON, France et CAMBRIDGE Mass., 24 juin 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), (« ERYTECH » ou la « Société »), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant des médicaments dans les globules rouges, annonce aujourd’hui le recentrage de ses activités de développement avec son produit candidat eryaspase pour le traitement potentiel de certaines indications choisies de tumeurs solides.
EYRYY ERYP

0
ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia

2018-06-24 globenewswire
LYON, France and CAMBRIDGE Mass., June 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will focus its development efforts for its product candidate eryaspase on the potential treatment of selected solid tumor indications.
EYRYY ERYP

0
ERYTECH to Present at JMP Securities Life Science Conference

2018-06-20 globenewswire
LYON, France, June 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the JMP Securities Life Science Conference, June 20, 2018 at The St. Regis, New York, in New York City.
EYRYY ERYP

0
General Meeting to be held on June 28, 2018 and Availability of Related Materials

2018-06-07 globenewswire
LYON, France, June 07, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced the availability of documents for its Annual General Meeting, to be held on June 28, 2018.
EYRYY ERYP

0
ERYTECH to Present Pharmacodynamic Data from Phase 2/3 Trial of Eryaspase in ALL at ASCO 2018

2018-06-04 globenewswire
LYON, France, June 04, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present pharmacodynamic characterization data from its Phase 2/3 trial of eryaspase (GRASPA®) in combination with chemotherapy for the treatment of relapsed acute lymphoblastic leukemia (ALL) at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2018 in Chicago, Illinois.
EYRYY ERYP

0
ERYTECH to Webcast Presentation at the Jefferies Global Healthcare Conference

2018-05-30 globenewswire
LYON, France, May 30, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the Jefferies Global Healthcare Conference on Wednesday, June 6, 2018 at The Grand Hyatt, in New York City.
EYRYY ERYP

49
Erytech Pharma's (EYRYY) CEO Gil Beyen on Q1 2018 Results - Earnings Call Transcript

2018-05-15 seekingalpha
Thank you. Good afternoon everybody in Europe, good morning in the U.S. Welcome to our Q1 Business Update and Financial Results Call. It’s the second one since we are a dual listed company Euronext and Nasdaq, so I’d draw double attention on Slide 2 on the disclaimer. And then jump quickly to the agenda. So as usual I’ll start with a business update, Eric will take over with the financial results the highlights for Q1, and also we’ll take the news flow and the milestones and then we’ll come back to Q&A, we’ll open the floor for Q&A.
EYRYY ARGS UTHR ERYP

49
ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy

2018-05-14 globenewswire
LYON, France, May 14, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it has appointed Alex Dusek as its Vice President Commercial Strategy and member of the executive team. Mr. Dusek brings 25 years of experience in market access, product marketing and sales across small biotech start-ups and multi-national pharmaceutical companies.
EYRYY ARGS UTHR ERYP

0
ERYTECH to Host First Quarter 2018 Conference Call and Business Update

2018-05-09 globenewswire
LYON, France, May 09, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2018 first quarter conference call and webcast on Tuesday, May 15, 2018, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.
EYRYY ERYP

0
ERYTECH annonce le dépôt de son Document de Référence 2017 et de son Form 20-F 2017

2018-04-24 globenewswire
LYON, France, 24 avr. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), société biopharmaceutique de stade clinique développant à partir de sa plateforme propriétaire d’encapsulation de médicaments dans les globules rouges des thérapies innovantes contre des formes sévères de cancers et des maladies orphelines, annonce avoir déposé auprès de l’Autorité des Marchés Financiers (AMF) en France son Document de Référence au titre de l′exercice clos le 31 décembre 2017 et son Form 20-F au titre de l′exercice clos le 31 décembre 2017 auprès de la « Securities and Exchange Commission » (SEC).
EYRYY ERYP

0
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F

2018-04-24 globenewswire
LYON, France, April 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.
EYRYY ERYP

161
Can Homology Sustain Success?

2018-04-11 seekingalpha
Homology is looking at a new way to advance gene editing, but its treatments will require substantive time to go through FDA approval.
EDIT EYRYY DMTX 4568 SYN CDXS NVS FIXX ERYP BMRN

55
ArGen-X started at buy with $125 stock price target at SunTrust RH

2018-04-09 marketwatch
Small- and mid-cap biotech stocks have displayed usual first quarter resilience, setting the stage for second quarter upside.
EYRYY ABYLY AKAO ERYP ABLX ABLYF

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...